You Know, I've Been There, I Know, It's Happening.

We love to hear from our listeners. Send us a message.

Purespring Therapeutics launched in 2020 on the back of IP developed by renowned kidney researcher Prof. Moin Saleem, who spent decades working on podocytes when podocytes weren’t cool. Just two years later, the company boasts three gene therapy assets and a platform developed expressly to identify new therapeutic targets to address kidney disease. These assets promise to change the "dialysis or transplant" ultimatums associated with kidney disease, where therapeutic innovation has been scarce. Under the leadership of CEO Richard Francis, the young company is operating with the audacious goal to take its therapeutics all the way to the commercial finish line. On this episode of the Business of Biotech, Francis offers a transparent look at the company’s growth strategy and the progress it’s achieved to date.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/